## Lonza

Managing QC Challenges in an Ever-changing Industry with MODA™ QC Micro Platform



### **Today's Presenters**

#### Mike Goetter

Innovation Director of Informatics *Informatics, Lonza Bioscience* 

#### Rob Lutskus

Product Delivery Manager of MODA Informatics, Lonza Bioscience



### **Forward Looking Statements**

Certain matters discussed in this presentation may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and Uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this presentation.



12-Jun-12 slide 3



# Lonza Overview A focused market leader

#### Corporate Overview:

- Life sciences driven company
- Headquartered in Basel (Switzerland)
- Sales of CHF 2.692 billion in 2011

#### Global operations:

- 45 major production and R&D facilities
- Employs over 11,000 people

#### Global leader in microbial control and custom manufacturing:

- Biologics contract
- Cell Therapy and Viral Filling
- Hygiene
- Water treatment
- Active pharmaceutical ingredients both chemical and biological

#### Leading positions in product market niches:

- Cell Therapy Manufacturing
- Endotoxin detection
- Cell-based research products
- Nutrition ingredients
- Performance intermediates





#### Lonza's Interconnected Life-science Platform

#### Lonza

Life Science Ingredients

Nutrition Ingredients

Performance Intermediates Microbial Control

Hygiene & Preservation

**Water Treatment** 

Materials Protection

**Personal Care** 

**Wood Treatment** 

**Custom Manufacturing** 

Chemical Manufacturing

Biological Manufacturing

Development Services

**Bioscience** 

**Clinical Services:** 

Cell and Viral
Therapeutic
Contract
Manufacturing
and Testing
Services

**Products:** 

Research Translational

#### Lonza


#### **Value Proposition**

- More science. Less paper.
  - Increase operational efficiency, improve quality, reduce costs
  - Quickly move from paper-intensive QC monitoring/analysis
  - Gain measurable ROI and significantly enhance compliance













### **Agenda**

- Recent regulatory guidance changes and their impacts on QC micro programs
- Managing requirements for monitoring and reporting in a global regulatory framework
- Meeting demands with limited resources: audits, excursion investigations, compliance deviations
- Cost savings and compliance improvement examples from MODA-EM™ customers
- What's new in MODA-EM™ version 3.1



- Microbiological Control and Monitoring of Aseptic Environments
  - Presents an entirely new perspective on environmental control relying on incident rates rather than action / alert levels
  - Reflects the uncertainty in microbial recovery, especially in the cleanest environments
  - Makes a clear distinction between environments for aseptic and other cleanroom applications



- Microbiological Control and Monitoring of Aseptic Environments relevant excerpts<sup>1</sup>:
  - "Since the early 1980s, manufacturers have established alert and action levels for environmental monitoring. In recent years, the numerical difference between alert and action levels has become quite small, especially in ISO 5 environments."
  - "As a result of this inherent variability and in determinate sampling error, the supposed differences between, for example, an alert level of 1 cfu and an action level of 3 cfu are not analytically significant. Treating differences that are within expected, and therefore, normal ranges as numerically different is not scientifically valid and can result in unwarranted activities."

<sup>1-</sup> United States Pharmacopeia, "<1116> Microbiological Control and Monitoring of Aseptic Processing Environments", *USP 35-NF30*, 703, 2012.



- Microbiological Control and Monitoring of Aseptic Environments relevant excerpts<sup>2</sup> (cont.):
  - "Because of the inherent variability of microbial sampling methods, contamination recovery rates are a more useful measure of trending results than is focusing on the number of colonies recovered from a given sample."
  - "The incident rate is the rate at which environmental samples are found to contain microbial contamination. For example, an incident rate of 1% would mean that only 1% of the samples taken have any contamination regardless of colony number. In other words, 99% of the samples taken are completely free of contamination"

<sup>2-</sup> United States Pharmacopeia, "<1116> Microbiological Control and Monitoring of Aseptic Processing Environments", *USP 35-NF30*, 703-706, 2012.



Table 2: Suggested Frequency of Sampling for Aseptic Processing Areas<sup>3</sup>

Sampling Areas	Frequency of Sampling
Critical zone (ISO Class 5 or better) Active air Surface monitoring	Each operating shift At the end of the operation
Aseptic processing area adjacent to critical zone  All sampling	Each operating shift
Other nonadjacent aseptic areas  All sampling	Once per day

<sup>3-</sup> United States Pharmacopeia, "<1116> Microbiological Control and Monitoring of Aseptic Processing Environments", *USP 35-NF30*, 702, 2012.



Table 3: Recommended Contamination Incident Rates<sup>4</sup>

Grade	Active Air	Settle Plate (4 hr Exposure)	Contact Plate or Swab	Glove or Garment
Isolator (ISO 5 or better)	<0.1%	<0.1%	<0.1%	<0.1%
ISO 5	<1%	<1%	<1%	<1%
ISO 6	<3%	<3%	<3%	<3%
ISO 7	<5%	<5%	<5%	<5%
ISO 8	<10%	<10%	<10%	<10%

<sup>4-</sup> United States Pharmacopeia, "<1116> Microbiological Control and Monitoring of Aseptic Processing Environments", *USP 35-NF30*, 703, 2012.



- Microbiological Control and Monitoring of Aseptic Environments relevant excerpts<sup>5</sup> (cont):
  - "Excursions beyond approximately 15 cfu recovered from a single ISO 5 sample, whether from airborne, surface, or personnel sources, should happen very infrequently. When such ISO 5 excursions do occur, they may be indicative of a significant loss of control when they occur within the ISO 5 critical zone in close proximity to product and components. Thus, any ISO 5 excursion >15 cfu should prompt a careful and thorough investigation. A key consideration for an abnormally high number of the recovered colonies is whether this incident is isolated or can be correlated with other recoveries. Microbiologists should review recovery rates for at least two weeks before the incident of abnormally high recovery so that they can be aware of other recoveries that might indicate an unusual pattern. The identity of the organisms recovered is an important factor in the conduct of this investigation."

5- United States Pharmacopeia, "<1116> Microbiological Control and Monitoring of Aseptic Processing Environments", *USP 35-NF30*, 703, 2012.




### **Addressing These Changes**


- Significant time investment
  - Rewriting SOPs
  - Reclassifying "incidents" and "trends"
  - New quarterly reports, excursion reports and investigation procedures
- Resource investment
  - Personnel to evaluate and make changes
  - Multi-department agreement on changes




- Test Based and Site Based Frequency Limits
  - Limits based on adverse trends for a given test or for all test methods at a site.













slide 17




 Powerful reports and analytics that identify adverse trends and correlate results across tests









05/30/201212:17:45PM

#### **Investigation Report Form** As of 05/30/2012






#### Previous 90 to Subsequent 15 day Excursions for Room / System (R1001)

<u>Date</u>	<u>Barcode</u>	<u>Site Name</u>	<u>Result</u>	<u>AlertLimit</u>	<u>ActionLimi</u>	<u>Deviation</u>	<u>Deviation</u> <u>Number</u>
<b>AirViable-cfu/1000L</b> 03/16/2010 2:09:20PM	00000BYS	R1001.1	17 cfu/1000L	N/A	>=1.00	Action	N/A
AirViable-cfu/m^3							
03/30/2010 7:20:31PM	00000C68	R1001.1	19cfu/m^3	N/A	>=1.00	Action	N/A
03/31/2010 11:57:57AM	00000BR2	R1001.3	17cfu/m^3	N/A	>=1.00	Action	N/A
04/13/2010 3:14:18PM	00000C8K	R1001.3	20 cfu/m^3	N/A	>=1.00	Action	N/A
05/17/2010 5:28:02PM	00000CD4	R1001.3	18 cfu/m^3	N/A	>=1.00	Action	N/A
05/18/2010 11:01:54AM	00000CDM	R1001.3	18 cfu/m^3	N/A	>=1.00	Action	N/A
05/21/2010 2:49:26PM	00000CG1	R1001.3	19cfu/m^3	N/A	>=1.00	Action	N/A
Personnel Monitoring	-cfu						
02/18/2010 2:40:02PM	,	R1001.5	16 cfu	N/A	>=1.00	Action	N/A
03/30/2010 7:20:27PM	00000C5VP1S1	R1001.5	15 cfu	N/A	>=1.00	Action	N/A
05/17/2010 5:27:58PM	00000CD2P1S2	R1001.5	8 cfu	N/A	>=1.00	Action	N/A
05/18/2010 11:01:18AM	00000CDKP1S1	R1001.5	17 cfu	N/A	>=1.00	Action	N/A
SettlePlates-cfu							
03/30/2010 7:20:31PM	00000C62	R1001.6	8 cfu	N/A	>=1.00	Action	N/A
05/13/2010 11:01:45AM	00000CB5	R1001.6	27 cfu	N/A	>=1.00	Action	N/A
SurfaceBioburden-cfi							
03/18/2010 8:46:34PM	00000BZK	R1001.8	25 cfu	N/A	>=1.00	Action	N/A
03/19/2010 4:52:11PM	MG453022	R1001.WS1	23 cfu	N/A	>=1.00	Action	N/A
03/22/2010 6:32:56AM	MG453037	R1001.WS1	14 cfu	N/A	>=1.00	Action	N/A
03/30/2010 7:20:31PM	00000C5Y	R1001.WS1	13 cfu	N/A	>=1.00	Action	N/A
03/30/2010 7:20:31PM	00000C5Z	R1001.WS2	6 cfu	N/A	>=1.00	Action	N/A
04/13/2010 1:59:01PM	00000C60	R1001.8	23 cfu	N/A	>=1.00	Action	N/A
05/17/2010 5:28:02PM	00000CD0	R1001.8	6 cfu	N/A	>=1.00	Action	N/A

#### Isolate Information for Room/System (R1001)

<u>Date</u>	<u>Sample</u>	<u>Location</u>	<u>IsolateName</u>
02/18/2010 2:40:32PM	00000BU3	R1001.3	Escherichiacoli
03/22/2010 6:32:56AM	MG453037	R1001.WS1	Aspergillus glaucus
04/13/2010 1:59:01PM	00000C60	R1001.8	Staphylococcus caprae
05/13/2010 11:01:45AM	00000CB1	R1001.WS1	Chryseobacterium indologenes
05/18/2010 11:01:54AM	00000CDM	R1001.3	Staphylococcus aureus
05/21/2010 2:49:26PM	00000CG1	R1001.3	Staphylococcus aureus







Beta Pharma
MODADMIN

02/21/2012 9:18:23PM

**Deviation Summary** 



Report Period from 01/01/2011 to 12/31/2011

Deviation	Sample	Sample Date	Sampled By	Site Name	Site Class	Result		Alert Limit	Action Limit	Deviation Type	Envir	onment
Beta Phar	maceuticals -> A	septic Core			Alert	s:	1	Actions:	2	9 Total:		30
R1001					Alert	s:	0	Actions:	1	2 Total:		12
Air	Viable (cfu/m^3	1)			Alert	s:	0	Actions:		8 Total:		8
838	00000K87	10/11/2011 11:31:24AM	Analyst02	R1001.1	A	50 cfu/n	n^3		1	Action	D	
818	000003U5	05/27/2011 3:05:58AM	Analyst08	R1001.1	A	36 cfu/n	n^3		1	Action	D	
778	00000IT7	02/07/2011 11:47:37AM	Analyst08	R1001.3	A	31 cfu/n	n^3		1	Action	D	
782	00000IT6	02/07/2011 11:47:37AM	Analyst08	R1001.3	A	42 cfu/n	n^3		1	Action	D	
779	00000IT8	02/07/2011 11:47:37AM	Analyst08	R1001.3	A	1 cfu/m	^3		1	Action	D	
Organism:	Staphylococcus Aureu	s,										
773	00000IRL	01/18/2011 6:07:11AM	Analyst08	R1001.3	A	31 cfu/n	n^3		1	Action	D	
Organism:	Staphylococcus Aureu	s,										
772	000001Q6	01/12/2011 10:03:10AM	Analyst08	R1001.3	A	1 cfu/m	^3		1	Action	D	
Organism:	Staphylococcus Epider	rmidis,										
771	000001Q5	01/12/2011 10:03:10AM	Analyst08	R1001.3	A	20 cfu/n	n^3		1	Action	D	
Set	tle Plates (cfu)				Alert	s:	0	Actions:		3 Total:		3
823	000003WH	06/08/2011 1:54:30PM	Analyst08	R1001.6	A	44 cfu			1	Action	D	
802	0000035U	03/17/2011 3:16:05PM	Analyst08	R1001.6	A	220 cfu			1	Action	D	
770	00000IOE	01/05/2011 4:25:14PM	Analyst08	R1001.6	A	15 cfu			1	Action	D	
Organism:	Bacillus Cereus,											
Sur	face Bioburden (	cfu)			Alert	s:	0	Actions:		1 Total:		1
813	00000351	05/23/2011 8:52:06PM	Analyst08	R1001.8	A	70 cfu			1	Action	D	
R1003					Alert	s:	1	Actions:	1	7 Total:		18
USWYL032:MODA_TE	ST_3_0_7			Copyright © 2011 L	onza Walkersville, Inc.							Page 1

slide 22




Beta Pharma MODADMIN 02/21/2012 9:14:49PM

#### Organisms By Location Chart

Report Period From 01/01/2011 to 12/31/2011







### **Doing More with Less**

- Most of the industry has experienced layoffs, hiring freezes or cutbacks at some level
- Less analysts doing the same or additional work
- More frequent and more demanding audits and audit requests
- Operating according to Lean Six Sigma practices



### Measurable Cost Savings

#### Lonza Walkersville

#### Estimated

- 1.3 hours/day x 3 beta sites = 3.9 hours/day
- 1.3 hours/day x 11 clean room suites = 14.3 hours/day
- 18.2 hours/day ÷ 8 hours day/analyst = 2.25 FTEs

#### Realized

- Staff reduction from 11 to 8 FTE's (~25%)
- Miscellaneous savings (binders, paper, ink, particle-counter tape, autoclave costs, archiving and storage of data)
- Shift of resource to other value-added activities



### Measurable Cost Savings

#### Mid-sized biotech:

- Opened new building which doubled sample volume in 2006
- Installed MODA<sup>™</sup>QC Micro Platform to coincide with building approval
- Gained efficiencies, improved workflow, and reduced redundancies without increasing staff
- Upgraded to MODA™ 3.0 platform in 2010
- Further process improvements realized with upgrade



### Lonza's Global MODA™-EM Deployment

- There were two sites using MODA™QC Micro Platform locally prior to the global project
- The main global project goal was to implement seven additional sites using the centralized approach as well as providing the capability to move the two local installations onto the corporate system
- This would also provide a platform to expand the global system to other Lonza sites in the future

#### Lonza

### **Currently There Are Eight Sites Live**



Tuas - Singapore



Verviers - Belgium



Walkersville, MD (USA)



Porriño - Spain

#### Lonza



Visp - Switzerland



Portsmouth, NH (USA)



Hopkinton, MA (USA)



Kouřim, Czech Republic



#### With Two Additional Sites for Future Installs



Slough, UK




Houston, TX (USA)



#### The Solution

#### MODA-EM™: Automates QC micro data collection & management



#### Lonza

### **MODA™** Solution: Components



#### MODA-EM™ Client

Software to manage the entire lifecycle of EM samples without paper

#### MODA-FDC™

Mobile Field Data Capture platform for sampling in all critical areas

#### MODA-EM™ Server

Database to store, administer, and report all EM data

#### **MODA-VIP™**

Visual Intelligence Portal, advanced visualization of EM data




### Global/Multi-site Deployment

MODA<sup>™</sup>-EM can be deployed as an enterprise application. Instances are typically site or cluster-specific, however:


- Server can reside either per-site placement or in datacenter
- Single or multi-server architecture supported through server virtualization
- Instances can be stored on a single database server (one schema per instance)
- Web service components can be hosted on a single IIS web server instance
- Authentication integrated with Active Directory and LDAP
- Authorized users can login between instances
- Reports can be deployed via Business Objects Enterprise Server or Crystal Reports Server



#### **Global/Multi-site Deployment**



- Users' rights are granted by a combination of user role and location
- A user in the US can sample just the US sites, while a global administrator in the EU can see all locations and have rights to modify them





#### MODA™-EM Version 3.1

#### Major update to address:

- New analytical tools and revamped reporting suite
- Customer-driven usability and paperless efficiency features
- Global rollout capabilities and improvements





### **Major Features/Objectives:**

- Multi-language support- support for eight languages (English, German, French, Italian, Spanish, Czech, Japanese, Portuguese -Brazil) with framework to rapidly add more
- Dashboard Live monitoring tool to capture real time data in a configurable format
- Ad-hoc reports Excel® plug-in that allows a secure, password required connection to the MODA™software to harness the power of the Excel® charting features
- Report improvements and updates numerous report enhancements and additional reports
  - 3D charts, product release reports and hit rate analysis




### Major Features/Objectives (cont.):

- Filtering and editing enhancements Updates to the interface allow more data to be edited within the application, with ease.
   The additional filters support supervisor responsibilities in searching for data or samples
- Session defaults set the media, equipment and product at the beginning of the sampling/testing session and the system will apply it automatically to all applicable samples
- Site based frequency limits trigger notifications based on all sampling done at a site, previously this was done on a per test basis




#### MODA™-EM Version 3.1





#### MODA™-EM Version 3.1



#### Lonza

#### MODA™-EM Version 3.1






### Major Features/Objectives (cont.):

- Data import/export tools end user interface to import to or export from MODA™ QC Micro Platform to other systems, including LIMS and spreadsheets
- SOP linkage connection to document management systems to connect your SOPs to the end users
- Complete API exchange data with other systems to the MODA™ platform using a service-oriented architecture with no end-user interaction
- New devices- numerous new device integrations (particle counters, conductivity meters, TOC analyzers) new tablet support, and improved support for WinKQCL™ software
- New notification services increased configurability of the notifications allowing time and frequency setting along with additional notification types




### **MODA™** Integration Examples





#### **MODA-EM Version 4.0**



To submit a question, use the "Ask Presenter a Question" feature (left side of your screen). If we do not answer a question online, we will be sure to follow up with an e-mail.

# Lonza

#### **Questions & Answers**



### **Upcoming Webinars**

**Topic: Cell-based Potency Assays—Expectations & Realities** 

Category: Viral-based Therapeutics

Date: Tuesday, July 10

Look for your invitation shortly!



### Wrap-up: More Information

Mike Goetter

Innovation Director of Informatics

Informatics, Lonza Bioscience

Email: michael.goetter@lonza.com

Rob Lutskus

Product Delivery Manager of MODA

Informatics, Lonza Bioscience

Email: robert.lutskus@lonza.com

Learn more about MODA Solution: <a href="https://www.lonza.com/moda">www.lonza.com/moda</a>

Or via email: <a href="mailto:scientific.support@lonza.com">scientific.support@lonza.com</a>

# Lonza

**Thank You**